

Outthink. Outperform.

## “Green shoots” has finally appeared

KPJ booked a RM34.1m net profit in 1Q16, making up 23% of our forecasts. We deem this in-line as 1Q is typically weaker due to seasonality. Revenue grew 5% yoy helped by both higher patient volume and revenue intensity. Patient volume has finally staged a comeback, growing by 1% yoy after three consecutive quarters of decline, suggesting that the GST-driven impact has finally worn off. **Maintain BUY with RM4.87 TP, based on SOTP valuation.**

### 1Q16 results in-line with expectations

KPJ reported a headline net profit of RM34.1m in 1Q16 (+1% yoy; +39% qoq), making up 22%/23% of our/consensus full year forecasts. This is in-line with our expectations, as 1Q is usually weaker due to seasonality. We expect earnings to pick-up in 2Q-3Q. Also, KPJ declared its first interim dividend of 1.8 sen per share, which is in-line with our expectations.

### Results analysis

Revenue grew to RM743.9m in 1Q16 (+5% yoy; +7% qoq), helped by higher patient volume (+1% yoy; +5% qoq) and higher revenue intensity (+4% yoy; +2% qoq). Gross margin was healthy at 31.2% in 1Q (flat yoy; +5.2ppts qoq), while administrative expenses remain steady at RM174.7m in the quarter (+2% yoy; +41% qoq due to seasonality). Share of associates' profit fell by 7% yoy to RM8.3m in 1Q16.

### “Green shoots” finally appeared in patient volume

Following three consecutive quarters of decline in patient volume, KPJ's volume has finally staged a comeback growing by 1% yoy in 1Q16. More commendable is that higher-margin inpatients (+4% yoy) actually outpaced outpatients (+1% yoy) in 1Q. All these suggest that the drag on business volume following the implementation of GST in Apr 2015 has started to wear off. If so, patient volume will likely resume its long-term growth trend, in-line with the group's expansion plan.

### Maintain BUY; raise TP to RM4.87

We tweaked our 2016/17/18E net profit forecasts by -2%/+0%/3%, after making some housekeeping adjustments following the finalisation of 2015 accounts. This led us to revise our SOTP-derived TP to RM4.87 (previous: RM4.90). Maintain BUY. Key risks include margin compression and declines in patient volume.

### Earnings & Valuation Summary

FYE 31 Dec	2014	2015	2016E	2017E	2018E
Revenue (RMm)	2,639.1	2,847.6	3,098.8	3,363.6	3,671.4
EBITDA (RMm)	301.3	332.1	375.7	438.2	497.3
Pretax profit (RMm)	218.1	209.6	223.8	242.6	258.6
Net profit (RMm)	143.0	135.3	146.7	158.0	167.8
EPS (sen)	14.1	13.0	13.9	15.0	15.9
PER (x)	30.1	32.4	30.4	28.2	26.6
Core net profit (RMm)	123.0	122.5	146.7	158.0	167.8
Core EPS (sen)	12.1	11.8	13.9	15.0	15.9
Core EPS growth (%)	27.9	(2.3)	17.8	7.7	6.2
Core PER (x)	35.0	35.8	30.4	28.2	26.6
Net DPS (sen)	7.4	6.9	7.5	8.0	8.5
Dividend Yield (%)	1.8	1.6	1.8	1.9	2.0
EV/EBITDA (x)	17.9	17.0	15.9	14.4	13.3
Chg in EPS (%)	-	-	(1.6)	0.4	2.8
Affin/Consensus (x)	-	-	0.9	0.9	0.9

Source: Company, Affin Hwang estimates

Affin Hwang Investment Bank Bhd (14389-U)  
(Formerly known as HwangDBS Investment Bank Bhd)

## Results Note

# KPJ Healthcare

KPJ MK  
Sector: Healthcare

**RM4.23 @ 19 May 2016**

**BUY (maintain)**

Upside: 15.1%

**Price Target: RM4.87**

Previous Target: RM4.90



## Price Performance

	1M	3M	12M
Absolute	0.0%	-2.8%	-0.2%
Rel to KLCI	+4.7%	-0.3%	+10.5%

## Stock Data

Issued shares (m)	1,041.7
Mkt cap (RMm)/(US\$m)	4,406.3/1,079.5
Avg daily vol - 6mth (m)	0.8
52-wk range (RM)	3.96-4.42
Est free float	30.1%
BV per share (RM)	1.42
P/BV (x)	2.99
Net cash/ (debt) (RMm) (1Q16)	(1,153.8)
ROE (2016E)	9.7%
Derivatives	Yes
Shariah Compliant	Yes

## Key Shareholders

Johor Corp	44.6%
EPF	12.5%
Waqaf An-Nur Corporation	7.3%

Source: Affin Hwang, Bloomberg

Tan Kee Hoong, CFA  
(603) 2146 7470  
keehoong.tan@affinhwang.com

Out think. Out perform.

Fig 1: Results comparison

FYE 31 Dec (RMm)	1QFY16	QoQ % chg	YoY % chg	3MFY16	YoY % chg	Comments
Revenue	743.9	7.2	4.8	743.9	4.8	Revenue grew 5% yoy on the back of higher patient volume and revenue intensity.
Op costs	(651.6)	6.6	4.2	(651.6)	4.2	
EBITDA	92.4	11.1	9.2	92.4	9.2	
<i>EBITDA margin (%)</i>	<i>12.4</i>	<i>0.4ppt</i>	<i>0.5ppt</i>	<i>12.4</i>	<i>0.5ppt</i>	
Depn and amort	(31.2)	(5.1)	1.2	(31.2)	1.2	
EBIT	61.1	21.7	13.8	61.1	13.8	
<i>EBIT margin (%)</i>	<i>8.2</i>	<i>1ppt</i>	<i>0.6ppt</i>	<i>8.2</i>	<i>0.6ppt</i>	
Int expense	(20.7)	52.2	42.0	(20.7)	42.0	
Int and other inc	2.7	80.4	5.3	2.7	5.3	
Associates & JVs	8.3	32.5	(6.7)	8.3	(6.7)	
EI	0.0	N/A	N/A	0.0	N/A	
<b>Pretax profit</b>	<b>51.4</b>	<i>(16.2)</i>	1.6	<b>51.4</b>	<i>(1.6)</i>	
<b>Core pretax</b>	<b>51.4</b>	15.9	1.6	<b>51.4</b>	1.6	
Tax	(14.8)	(14.7)	3.9	(14.8)	3.9	
<i>Tax rate (%)</i>	<i>28.8</i>	<i>-10.4ppt</i>	<i>0.7ppt</i>	<i>28.8</i>	<i>0.7ppt</i>	
MI	(2.5)	(5.3)	(1.4)	(2.5)	1.4	
<b>Net profit</b>	<b>34.2</b>	<i>(39.0)</i>	0.8	<b>34.2</b>	0.8	
EPS (sen)	3.2	(39.3)	0.5	3.2	(0.5)	
<b>Core net profit</b>	<b>34.2</b>	38.4	0.8	<b>34.2</b>	0.8	In-line with expectations

Source: Affin Hwang, company data

Fig 2: SOTP valuation for KPJ Healthcare

	Value (RM m)	Value per share (RM)	Remarks
Hospital operations	4,692.3	4.45	NPV of FCFF less net debt; WACC = 7.2%, LTG =2%
49% stake in Al-Aqar REIT	461.6	0.44	6% 2016E yield
Other associates & JVs	61.5	0.06	10x 2016E P/E
<b>SOTP-Equity Value</b>	<b>5,215.4</b>	<b>4.95</b>	Current share base of 1,054.5m
Add: Potential proceeds from warrants conversion	347.4		Exercise price of RM4.01; 86.6m warrants outstanding
<b>Diluted Equity Value</b>	<b>5,562.7</b>	<b>4.87</b>	Diluted share base of 1,141.1m

Source: Affin Hwang, Company data

**Equity Rating Structure and Definitions**


---

<b>BUY</b>	Total return is expected to exceed +10% over a 12-month period
<b>HOLD</b>	Total return is expected to be between -5% and +10% over a 12-month period
<b>SELL</b>	Total return is expected to be below -5% over a 12-month period
<b>NOT RATED</b>	Affin Hwang Investment Bank Berhad does not provide research coverage or rating for this company. Report is intended as information only and not as a recommendation

*The total expected return is defined as the percentage upside/downside to our target price plus the net dividend yield over the next 12 months.*

<b>OVERWEIGHT</b>	Industry, as defined by the analyst's coverage universe, is expected to outperform the KLCI benchmark over the next 12 months
<b>NEUTRAL</b>	Industry, as defined by the analyst's coverage universe, is expected to perform inline with the KLCI benchmark over the next 12 months
<b>UNDERWEIGHT</b>	Industry, as defined by the analyst's coverage universe is expected to under-perform the KLCI benchmark over the next 12 months

---

This report is intended for information purposes only and has been prepared by Affin Hwang Investment Bank Berhad (14389-U) (formerly known as HwangDBS Investment Bank Berhad) ("the Company") based on sources believed to be reliable. However, such sources have not been independently verified by the Company, and as such the Company does not give any guarantee, representation or warranty (express or implied) as to the adequacy, accuracy, reliability or completeness of the information and/or opinion provided or rendered in this report. Facts, information, views and/or opinion presented in this report have not been reviewed by, may not reflect information known to, and may present a differing view expressed by other business units within the Company, including investment banking personnel. Reports issued by the Company, are prepared in accordance with the Company's policies for managing conflicts of interest arising as a result of publication and distribution of investment research reports. Under no circumstances shall the Company, its associates and/or any person related to it be liable in any manner whatsoever for any consequences (including but are not limited to any direct, indirect or consequential losses, loss of profit and damages) arising from the use of or reliance on the information and/or opinion provided or rendered in this report. Any opinions or estimates in this report are that of the Company, as of this date and subject to change without prior notice. Under no circumstances shall this report be construed as an offer to sell or a solicitation of an offer to buy any securities. The Company and/or any of its directors and/or employees may have an interest in the securities mentioned therein. The Company may also make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

Comments and recommendations stated here rely on the individual opinions of the ones providing these comments and recommendations. These opinions may not fit to your financial status, risk and return preferences and hence an independent evaluation is essential. Investors are advised to independently evaluate particular investments and strategies and to seek independent financial, legal and other advice on the information and/or opinion contained in this report before investing or participating in any of the securities or investment strategies or transactions discussed in this report.

Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data.

The Company's research, or any portion thereof may not be reprinted, sold or redistributed without the consent of the Company.

The Company, is a participant of the Capital Market Development Fund-Bursa Research Scheme, and will receive compensation for the participation.

This report is printed and published by:  
 Affin Hwang Investment Bank Berhad (14389-U)  
 (formerly known as HwangDBS Investment Bank Berhad)  
 A Participating Organisation of Bursa Malaysia Securities Bhd  
 Chulan Tower Branch,  
 3rd Floor, Chulan Tower,  
 No 3, Jalan Conlay,  
 50450 Kuala Lumpur.  
 www.affinhwang.com  
 Email : affin.research@affinhwang.com  
 Tel : + 603 2143 8668  
 Fax : + 603 2145 3005